Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;35(1):21-25.
doi: 10.36141/svdld.v35i1.6979. Epub 2018 Apr 28.

Non-tuberculous mycobacterial pulmonary disease: an Italian National survey

Bruno Del Prato  1 , Alfonso Maria Altieri  2 , Biagio Carlucci  3 , Pier Anselmo Mori  4 , Roberto Parrella  5 , Anna Stainer  6 , Federica De Giacomi  6 , Alberto Pesci  6 , Paola Faverio  6 ; Gruppo di Studio AIPO “Patologie Infettive Respiratorie e Tubercolosi”
Affiliations

Non-tuberculous mycobacterial pulmonary disease: an Italian National survey

Bruno Del Prato et al. Sarcoidosis Vasc Diffuse Lung Dis. 2018.

Abstract

The incidence of non-tuberculous mycobacteria (NTM) infection is increasing in Europe. However, a picture of Italian epidemiology and clinical practice is missing. We performed a national Italian survey involving 42 respiratory medicine departments. The NTM species more frequently isolated were Mycobacterium avium complex, followed by M. xenopi and M. kansasii. Patients with NTM were more frequently female (57%), and over 60 years of age, with bronchiectasis and COPD as main comorbidities. Bronchoscopic samples were widely used in the diagnostic phase. Of all patients with NTM, 73% met the criteria for NTM pulmonary disease. Despite strong adherence to the guidelines, physicians found significant difficulties related to pharmacological adverse events, patients' compliance and poor outcomes. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 21-25).

Keywords: epidemiology; non-tuberculous mycobacterial pulmonary disease; survey.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Geographic location of respiratory medicine centers responding to the survey
None
None
None
None
See this image and copyright information in PMC

References

    1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416. - PubMed
    1. Larsson L-O, Polverino E, Hoefsloot W, et al. Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives. Expert Rev Respir Med. 2017 Oct;10:1–13. - PubMed
    1. Rindi L, Garzelli C. Increase in non-tuberculous mycobacteria isolated from humans in Tuscany, Italy, from 2004 to 2014. Bmc Infect Dis. 2016 Feb 1;16:44. - PMC - PubMed
    1. Mencarini J, Cresci C, Simonetti MT, et al. Non-tuberculous mycobacteria: epidemiological pattern in a reference laboratory and risk factors associated with pulmonary disease. Epidemiol Infect. 2017 Feb;145(3):515–22. - PMC - PubMed
    1. Wallace RJ, Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014 Aug;146(2):276–82. - PMC - PubMed

LinkOut - more resources